X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs VENUS REMEDIES - Comparison Results

WOCKHARDT    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT VENUS REMEDIES WOCKHARDT/
VENUS REMEDIES
 
P/E (TTM) x -13.9 -1.5 - View Chart
P/BV x 1.6 0.1 1,538.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT   VENUS REMEDIES
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
VENUS REMEDIES
Mar-18
WOCKHARDT/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,012126 803.8%   
Low Rs53261 869.9%   
Sales per share (Unadj.) Rs355.9301.8 117.9%  
Earnings per share (Unadj.) Rs-60.3-24.9 242.4%  
Cash flow per share (Unadj.) Rs-46.82.5 -1,837.7%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.8293.3 87.9%  
Shares outstanding (eoy) m110.6312.34 896.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.3 700.0%   
Avg P/E ratio x-12.8-3.8 340.6%  
P/CF ratio (eoy) x-16.536.7 -44.9%  
Price / Book Value ratio x3.00.3 939.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3791,154 7,399.8%   
No. of employees `0006.30.9 676.1%   
Total wages/salary Rs m9,371393 2,383.8%   
Avg. sales/employee Rs Th6,295.04,026.1 156.4%   
Avg. wages/employee Rs Th1,498.3425.0 352.6%   
Avg. net profit/employee Rs Th-1,066.3-331.8 321.4%   
INCOME DATA
Net Sales Rs m39,3693,724 1,057.1%  
Other income Rs m1,20223 5,343.6%   
Total revenues Rs m40,5713,747 1,082.9%   
Gross profit Rs m18395 4.6%  
Depreciation Rs m1,495338 442.0%   
Interest Rs m2,555354 721.1%   
Profit before tax Rs m-2,830-275 1,027.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m25732 813.3%   
Profit after tax Rs m-6,669-307 2,172.9%  
Gross profit margin %010.6 0.4%  
Effective tax rate %-9.1-11.5 79.1%   
Net profit margin %-16.9-8.2 205.5%  
BALANCE SHEET DATA
Current assets Rs m33,7962,638 1,281.3%   
Current liabilities Rs m26,9172,305 1,167.9%   
Net working cap to sales %17.58.9 195.4%  
Current ratio x1.31.1 109.7%  
Inventory Days Days79135 58.6%  
Debtors Days Days8946 192.6%  
Net fixed assets Rs m39,6644,871 814.3%   
Share capital Rs m553123 448.3%   
"Free" reserves Rs m27,9683,496 800.1%   
Net worth Rs m28,5223,619 788.1%   
Long term debt Rs m21,7311,374 1,581.1%   
Total assets Rs m81,6207,509 1,087.0%  
Interest coverage x-0.10.2 -48.2%   
Debt to equity ratio x0.80.4 200.6%  
Sales to assets ratio x0.50.5 97.2%   
Return on assets %-5.00.6 -798.4%  
Return on equity %-23.4-8.5 275.7%  
Return on capital %-7.71.6 -485.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m9,8070-   
Fx outflow Rs m1,789517 346.3%   
Net fx Rs m8,019-517 -1,552.5%   
CASH FLOW
From Operations Rs m684514 133.0%  
From Investments Rs m6,302-123 -5,119.7%  
From Financial Activity Rs m-7,695-387 1,987.8%  
Net Cashflow Rs m-6644 -15,809.5%  

Share Holding

Indian Promoters % 74.5 32.9 226.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.2 1,277.8%  
FIIs % 7.7 0.6 1,327.6%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 66.4 23.2%  
Shareholders   67,757 20,121 336.7%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare WOCKHARDT With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and IT Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector and IT sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Mar 20, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - AUROBINDO PHARMA COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS